Liraglutide Therapy and Weight Control in Adolescents with Severe Obesity: A Real-World Experience
OBJECTIVE: Adolescent obesity remains a major clinical challenge, with limited effective treatment options beyond lifestyle modification. Liraglutide, a glucagon-like peptide-1 receptor agonist approved for adolescents aged ≥ 12 years, has shown promising results in clinical trials; however, real-world data remain scarce. This study aimed to evaluate the real-world effectiveness and tolerability of liraglutide in adolescents with severe obesity, including weight, body composition, and metabolic outcomes. METHODS: This retrospective longitudinal cohort study included adolescents with obesity aged 12-19 years who received liraglutide therapy. Anthropometric, biochemical, body composition, and adverse event data were assessed monthly. RESULTS: A total of 29 adolescents with obesity (13 males) were included (mean age: 15.7 ± 2.0 years; mean body mass index (BMI): 38.6 ± 6.0 kg/m2; body mass index standard deviation score (BMI-SDS): 3.38 ± 0.57). - BMI-SDS decreased progressively, with an estimated reduction of 0.46 from baseline to month 6; the decline was numerically faster in the first 3 months than in months 3-6, without reaching statistical significance (P = .11). Lean mass percentage increased and total fat percentage decreased after 3 months (both P < .05). Total cholesterol, fasting insulin, and homeostasis model assessment of insulin resistance decreased significantly, while other metabolic parameters remained unchanged. Gastrointestinal adverse events were common; 3 patients discontinued due to intolerance and 1 due to gallstones. CONCLUSION: In this real-world cohort, liraglutide treatment was associated with early and clinically meaningful reductions in BMI-SDS and improvements in insulin sensitivity in adolescents with severe obesity. The therapy was generally well tolerated, though gastrointestinal side effects and financial barriers limited treatment persistence. Longer-term prospective studies are needed to assess durability and cardiometabolic outcomes.
Authors
- Ilayda Altun (ORCID: https://orcid.org/0000-0002-2329-9223)
- Gökçe Velioğlu Haşlak (ORCID: https://orcid.org/0000-0001-9535-3295)
- Hande Turan (ORCID: https://orcid.org/0000-0003-0121-3756)
- Hasan Karakaş (ORCID: https://orcid.org/0000-0003-2282-2606)
- Olcay Evliyaoğlu (ORCID: https://orcid.org/0000-0003-4851-8637)
- Elvan Bayramoğlu (ORCID: https://orcid.org/0000-0002-6732-8823)
- Gürkan Tarçın (ORCID: https://orcid.org/0000-0002-1874-7570)
- Didem Güneş Kaya (ORCID: https://orcid.org/0000-0003-0791-916X)
- Mert Uçar (ORCID: https://orcid.org/0000-0003-0635-2958)
Institutions
- Istanbul University-Cerrahpaşa (TR)
- Kocaeli Üniversitesi (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Turkish Archives of Pediatrics
- Published
- 2026-11-19
- DOI
- https://doi.org/10.65717/turkarchpediatr.2026.26191
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00